Ketamine for chronic pain: Risks and benefits

British Journal of Clinical Pharmacology

Volumn 77, Issue 2, 2014, Pages 357-367

  Niesters, Marieke ^a   Martini, Christian ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chronic pain; ketamine; ketamine abuse; neuropathic pain; NMDA receptor antagonist; pain

Indexed keywords

ESKETAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANALGESIA; ARTICLE; CHRONIC PAIN; COST BENEFIT ANALYSIS; DRUG MECHANISM; HALLUCINATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEMORY DISORDER; NAUSEA; NEUROPATHIC PAIN; PANIC; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; SOMNOLENCE; TACHYCARDIA; VOMITING;

CHRONIC PAIN; KETAMINE; KETAMINE ABUSE; NEUROPATHIC PAIN; NMDA RECEPTOR ANTAGONIST; PAIN;

ANALGESICS; ANESTHETICS, DISSOCIATIVE; ANIMALS; CHRONIC PAIN; DRUG MONITORING; HUMANS; KETAMINE; NEURALGIA; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84893124516     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12094     Document Type: Article

References (88)

1. Okie S,. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-1985.
2. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD,. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85: S3-14.
3. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH,. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.
4. Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous MS, Marinus J, Sarton EY, Dahan A,. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009; 145: 304-311.
5. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H,. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparisonwith morphine and placebo. Pain 1994; 58: 347-354.
6. Kvarnstrom A, Karlsten R, Quiding H, Emanuelsson BM, Gordh T,. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003; 47: 868-877.
7. Coppel DL, Bovill JG, Dundee JW,. The taming of ketamine. Anaesthesia 1973; 28: 293-296.
8. Domino EF,. Taming the ketamine tiger. Anesthesiology 2010; 113: 876-886.
9. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A,. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010; 11: 2417-2429.
10. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T,. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003; 24: 37-43.
11. Reves JG, Glass PSA, Lubarsky DA, McEvoy MD,. Intravenous nonopioid anesthetics. In: Miller's Anesthesia, 6th edn, ed., Miller RD,. Philadelphia, PA: Elsevier, Churchill, Livingstone, 2005; 319.
12. Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E, Olofsen E,. S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology 2009; 111: 892-903.
13. Schüttler J, Stanski DR, White PF, Trevor AJ, Horai Y, Verotta D, Sheiner LB,. Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 1987; 15: 241-253.
14. Herd DW, Anderson BJ, Keene NA, Holford N,. Investigating the pharmacodynamics of ketamine in children. Ped Anesth 2008; 18: 36-42.
15. Dahan A, Olofsen E, Sigtermans M, Noppers I, Niesters M, Aarts L, Bauer M, Sarton E,. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011; 15: 258-267.
16. Hijazi Y, Boulieu R,. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30: 853-858.
17. Leung LY, Baillie TA,. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986; 29: 2396-2399.
18. Woolf TF, Adams JD,. Biotransformation of ketamine, (Z)-6- hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations. Xenobiotica 1987; 17: 839-847.
19. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, Olkkola KT,. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2010; 14: 625-629.
20. Noppers I, Olofsen E, Niesters M, Aarts L, Mooren R, Dahan A, Kharasch E, Sarton E,. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology 2011; 114: 1435-1445.
21. Olofsen Olofsen E, Noppers I, Niesters M, Kharasch E, Aarts L, Sarton E,. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology 2012; 117: 353-364.
22. Goldberg ME, Torjman MC, Schwartzman RJ, Mager DE, Wainer IW,. Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. Pain Physician 2010; 13: 379-387.
23. Petrenko AB, Yamakura T, Baba H, Shimoji K,. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003; 97: 1108-1116.
24. Marchand F, Perretti M, McMahon SB,. Role of immune system in chronic pain. Nat Rev Neurosci 2005; 6: 521-532.
25. Watkins LR, Maier SF,. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Int Med 2005; 257: 139-155.
26. Costigan M, Scholz J, Woolf CJ,. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32: 1-32.
27. Ossipov MH, Dussor GO, Porreca F,. Central modulation of pain. J Clin Invest 2010; 120: 3779-3787.
28. Woolf CJ,. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152: S2-15.
29. Niesters M, Khalili-Mahani N, Martini C, Aarts L, van, Gerven J, van, Buchem MA, Dahan A, Rombouts S,. Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo controlled functional magnetic resonance imaging study in healthy volunteers. Anesthesioloy 2012; 117: 868-877.
30. Niesters M, Aarts L, Sarton E, Dahan A,. Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo controlled cross-over study. Br J Anaesth 2013. [Epub ahead of print].
31. Hirota K, Lambert DG,. Ketamine: new uses for an old drug? Br J Anaesth 2011; 107: 123-126.
32. Wolff K, Winstock AR,. Ketamine: from medicine to misuse. CNS drugs 2006; 20: 199-218.
33. Sarton E, Teppema LJ, Olievuer C, Nieuwenhuijs D, Matthes HWD, Kieffer BL, Dahan A,. The involvement of the μ-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg 2001; 93: 1495-1500.
34. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, Sirinathsinghji D, Hill RG, Rupniak NM,. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunits in dorsal horn. Neuropharmacology 1999; 38: 611-623.
35. Niesters M, Dahan A, Swartjes M, Noppers I, Fillingim RB, Aarts L, Sarton EY,. Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain 2011; 152: 656-663.
36. Noppers I, Niesters M, Swartjes M, Bauer M, Aarts L, Geleijnse N, Mooren R, Dahan A, Sarton E,. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain 2011; 15: 942-949.
37. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M,. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009; 147: 107-115.
38. Amr YM,. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician 2010; 13: 245-249.
39. Wilson JA, Nimmo AF, Fleetwood-Walker SM, Colvin LA,. A randomised double blind trial of the effect of pre-emptive epidural ketamine on persistent pain after lower limb amputation. Pain 2008; 135: 108-118.
40. Mendola C, Cammarota G, Netto R, Cecci G, Pisterna A, Ferrante D, Casadio C, Della Corte F,. S(+)-ketamine for control of perioperative pain and prevention of Post Thoracotomy Pain Syndrome: a randomized, double blind study. Minerva Anestesiol 2012; 78: 757-766.
41. Dualé C, Sibaud F, Guastella V, Vallet L, Gimbert YA, Taheri H, Filaire M, Schoeffler P, Dubray C,. Perioperative ketamine does not prevent chronic pain after thoracotomy. Eur J Pain 2009; 13: 497-505.
42. Bell RF, Dahl JB, Moore RA, Kalso E,. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; (1): CD004603.
43. Bell RF, Eccleston C, Kalso E,. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage 2003; 26: 867-875.
44. Juni A, Klein G, Kest B,. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems. Brain Res 2006; 1070: 35-44.
45. Juni A, Klein G, Pintar JE, Kest B,. Nociception increases during opioid infusion in opioid receptor triple knock-out mice. Neuroscience 2007; 147: 439-444.
46. van Dorp E, Kest B, Kowalczyk WJ, Morariu AM, Waxman AR, Arout CA, Dahan A, Sarton E,. Morphine-6β-glucuronide rapidly increases pain sensitivity independently of opioid receptor activity in mice and humans. Anesthesiology 2009; 110: 1356-1363.
47. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH,. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
48. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK,. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
49. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS,. mTOR-dependent synapse formation underlies rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
50. Bowdle AT, Radant AD, Cowley DS, Kharash ED, Strassman RJ, Ray-Byrne PP,. Psychedelic effects of ketamine in healthy volunteers. Anesthesiology 1998; 88: 82-88.
51. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC,. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry 2006; 189: 173-179.
52. Coull JT, Morgan H, Cambridge VC, Moore JW, Giorlando F, Adapa R, Corlett PR, Fletcher PC,. Ketamine perturbs perception of the flow of time in healthy volunteers. Psychopharmacology 2011; 218: 543-556.
53. Morgan CJ, Curran VH,. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology 2006; 188: 408-424.
54. Cvrček P,. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 2008; 9: 253-257.
55. Blagrove M, Morgan CJ, Curran VH, Bromley L, Brandner B,. The incidence of unpleasant dreams after sub-anaesthetic ketamine. Psychopharmacology 2009; 203: 109-120.
56. Stefanovic A, Brandner B, Klaassen E, Cregg R, Nagaratnam M, Bromley LM, Das RK, Rossell SL, Morgan CJ, Curran HV,. Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia? J Clin Psychopharmacol 2009; 29: 124-133.
57. Honey GD, O'Loughlin C, Turner DC, Pomarol-Clotet E, Corlett PR, Fletcher P,. The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modeling of core symptoms of schizophrenia. Neuropsychopharmacology 2006; 31: 413-423.
58. Bergman SA,. Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 1999; 46: 10-20.
59. Morgen CJ, Rossell S, Pepper F, Smart J, Blackburn J, Brandner B, Curran HV,. Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users. Biol Psychiatry 2006; 59: 265-272.
60. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran VH,. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004; 29: 208-218.
61. Adler CM, Goldberg TE, Malholtra AK, Pickar D, Breier A,. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 1998; 43: 811-816.
62. Koffler SP, Hampstead BM, Irani F, Tinker KRT, Rohr P, Schwartzman RJ,. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol 2007; 22: 919-929.
63. Timm C, Linstedt U, Weiss T, Zenz M, Maier C,. Sympathicomimetische Effekte auch bei niedriger Dosierung von Esketamin. Anaesthetist 2008; 57: 338-346.
64. Kalsi SS, Wood DM, Dargan PI,. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J 2011; 4: 7107. doi: 10.3402/ehtj.v4i0.7107.
65. Blunnie WP, Zacharias M, Dundee JW, Doggart JR, Moore J, McIlroy PD,. Liver enzymes with continuous intravenous anaesthesia. Anaesthesia 1981; 36: 152-156.
66. Dundee JW, Fee JP, Moore J, McIlroy PD, Wilson DB,. Changes in serum enzyme levels following ketamine infusions. Anaesthesia 1980; 35: 12-16.
67. Kiefer RT, Rohr P, Ploppa A, Dietrich HJ, Grothusen J, Koffler S, Altemeyer KH, Unertl K, Schwartzman RJ,. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med 2008; 9: 1173-1201.
68. Noppers IM, Niesters M, Aarts LP, Bauer MC, Drewes AM, Dahan A, Sarton E,. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain 2011; 152: 2173-2178.
69. Weiner AL, Vieira L, McKay CA Jr, Bayer MJ,. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000; 18: 447-451.
70. Ng SH, Tse ML, Ng HW, Lau FL,. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 2010; 16: 6-11.
71. Morgan CJ, Curran VH,. Ketamine use: a review. Addiction 2011; 107: 27-38.
72. Middela S, Pearce I,. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract 2011; 65: 27-30.
73. Mak SK, Chan MT, Bower WF, Yip SK, Hou SS, Wu BB, Man CY,. Lower urinary tract changes in young adults using ketamine. J Urol 2011; 186: 610-614.
74. Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, Tse JM, Lau FL, Yiu MK, Man CW,. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 2008; 102: 1616-1622.
75. Mason K, Cottrell AM, Corrigan AG, Gillatt DA, Mitchelmore AE,. Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin Radiol 2010; 65: 795-800.
76. Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY,. Ketamine-associated bladder dysfunction. Int J Urol 2009; 16: 826-829.
77. Cheung RY, Chan SS, Lee JH, Pang AW, Choy KW, Chung TK,. Urinary symptoms and impaired quality of life in female ketamine users: persistence after cessation of use. Hong Kong Med J 2011; 17: 267-273.
78. Lo RS, Krishnamoorthy R, Freeman JG, Austin AS,. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singapore Med J 2011; 52: e52-55.
79. Wong SW, Lee KF, Wong J, Ng WW, Cheung YS, Lai PB,. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J 2009; 15: 53-56.
80. Poon TL, Wong KF, Chan MY, Fung KW, Chu SK, Man CW, Yiu MK, Leung SK,. Upper gastrointestinal problems in inhalational ketamine abusers. J Dig Dis 2010; 11: 106-110.
81. Curran VH, Monaghan L,. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001; 96: 749-760.
82. Morgan CJ, Riccelli M, Maitland CH, Curran VH,. Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend 2004; 75: 301-308.
83. Morgan CJ, Monaghan L, Curran VH,. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004; 99: 1450-1461.
84. Freeman TP, Morgan CJ, Klaassen E, Das RK, Stefanovic A, Brandner B, Curran VH,. Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans. Psychopharmacology 2009; 206: 563-573.
85. Sikker W, Zou X, Hotchkins CE, Divine RL, Sadovova N, Twaddle NC, Doerge DR, Scallet AC, Patterson TA, Hanig JP, Paule MG, Wang C,. Ketamine-induced neuronal cell death in perinatal rhesus monkey. Toxicol Sci 2007; 98: 145-158.
86. Jevtovic-Todorovic V, Carter LB,. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brains. Neurobiol Aging 2005; 26: 947-956.
87. Liao Y, Tang J, Corlett PR, Wang X, Yang M, Chen H, Liu T, Chen X, Hao W, Fletcher PC,. Reduced dorsal frontal gray matter after chronic ketamine use. Biol Psychiatry 2011; 69: 42-48.
88. Liao Y, Tang J, Ma M, Wu Z, Yang M, Wang X, Liu T, Chen X, Fletcher PC, Hao W,. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain 2010; 133: 2115-2122.